Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone

Abstract excerpt

Previous literature suggests that cytogenetics may be used for risk-adapted therapy in patients with relapsed/refractory multiple myeloma (MM) treated with lenalidomide and dexamethasone. However, the significance of each abnormality is still unclear, and chromosome 1 abnormalities have yet to be studied in this population. We therefore evaluated genetic risk factors including chromosome 1q gain and 1p loss by...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Multiple Myeloma Research and Treatments
• Share to PI3K/AKT/mTOR signaling in cancer
• Share to Protein Degradation and Inhibitors